Aptorum Group Limited is a United Kingdom-based clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. We show 3 historical shares outstanding datapoints in our APM shares outstanding history coverage, used to compute APM market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing APM market cap history over the course of time is important for investors
interested in comparing APM's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of APM versus a peer is one thing; comparing
APM market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like APM can fluctuate over the course of history.
With this page we aim to empower investors researching APM by allowing them to research the APM market cap history. |
Free APM Email Alerts:
Video: The Importance of Market Cap
